Evidence map›Paper›PMID 32197644›Full record

ArticleMicrobiome2020

Discovery of a novel integron-borne aminoglycoside resistance gene present in clinical pathogens by screening environmental bacterial communities.

Maria-Elisabeth Böhm, Mohammad Razavi, Nachiket P Marathe, Carl-Fredrik Flach, D G Joakim Larsson

Open access · goldAbstract read
In one paragraph

Article in Microbiome, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Antibiotic resistance in the environment.Nature reviews. Microbiology · 2022
    Review
  15. Article
  16. Review
  17. Article
  18. The Natural History of Integrons.Microorganisms · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Maria-Elisabeth BöhmCentre for Antibiotic Resistance Research (CARe), University of Gothenburg, Gothenburg, Sweden.
Mohammad RazaviCentre for Antibiotic Resistance Research (CARe), University of Gothenburg, Gothenburg, Sweden.
Nachiket P MaratheCentre for Antibiotic Resistance Research (CARe), University of Gothenburg, Gothenburg, Sweden.
Carl-Fredrik FlachCentre for Antibiotic Resistance Research (CARe), University of Gothenburg, Gothenburg, Sweden.
D G Joakim LarssonCentre for Antibiotic Resistance Research (CARe), University of Gothenburg, Gothenburg, Sweden. joakim.larsson@fysiologi.gu.se.
University of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew antibiotic resistance determinants are generally discovered too late, long after they have irreversibly emerged in pathogens and spread widely. Early discovery of resistance genes, before or soon after their transfer to pathogens could allow more effective measures to monitor and reduce spread, and facilitate genetics-based diagnostics.

resultsWe modified a functional metagenomics approach followed by in silico filtering of known resistance genes to discover novel, mobilised resistance genes in class 1 integrons in wastewater-impacted environments. We identified an integron-borne gene cassette encoding a protein that conveys high-level resistance against aminoglycosides with a garosamine moiety when expressed in E. coli. The gene is named gar (garosamine-specific aminoglycoside resistance) after its specificity. It contains none of the functional domains of known aminoglycoside modifying enzymes, but bears characteristics of a kinase. By searching public databases, we found that the gene occurs in three sequenced, multi-resistant clinical isolates (two Pseudomonas aeruginosa and one Luteimonas sp.) from Italy and China, respectively, as well as in two food-borne Salmonella enterica isolates from the USA. In all cases, gar has escaped discovery until now.

conclusionTo the best of our knowledge, this is the first time a novel resistance gene, present in clinical isolates, has been discovered by exploring the environmental microbiome. The gar gene has spread horizontally to different species on at least three continents, further limiting treatment options for bacterial infections. Its specificity to garosamine-containing aminoglycosides may reduce the usefulness of the newest semisynthetic aminoglycoside plazomicin, which is designed to avoid common aminoglycoside resistance mechanisms. Since the gene appears to be not yet common in the clinics, the data presented here enables early surveillance and maybe even mitigation of its spread.

Indexed as

IntegronsMicrobiotaAminoglycosidesAnti-Bacterial AgentsBacteriaDrug Resistance, BacterialEscherichia coliMetagenomicsMicrobial Sensitivity TestsWastewaterAminoglycosidesAnti-Bacterial AgentsWastewaterAminoglycosidesAntibiotic resistanceEnvironmentFunctional metagenomicsIntegronPathogens

Identifiers

PMID32197644
PMCPMC7085159
OpenAlexW3012866150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.